Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
A widely accepted mechanism to differentiate hESCs into card
2021-06-18

A widely accepted mechanism to differentiate hESCs into cardiomyocytes is through perturbation of the canonical Wnt/β-catenin pathway. Initial Wnt activation is required to form the Olanzapine [3]. Thereafter, it is believed that inhibition of the canonical Wnt/β-catenin pathway is pivotal for card
-
Our results for imidacloprid were unexpected considering tha
2021-06-18

Our results for imidacloprid were unexpected: considering that imidacloprid (Im) is a neonicotinoid insecticide with a different mode of action (agonist of the nicotinic cam kinase receptor) than OPs, we expected Es-ChE and T-ChE activity to be largely insensitive to changes in Im concentrations. H
-
NPC L NPC Niemann Pick C like
2021-06-18

NPC1L1 (NPC1 [Niemann-Pick C-like-1]-like intracellular cholesterol transporter) is the rate-limiting transmembrane transporter for cholesterol Piperaquine from the intestinal lumen, and it mediates the absorption of both dietary and biliary cholesterol., , NPC1L1 is the target of the cholesterol-lo
-
The selective estrogen receptor modulators SERMs
2021-06-18

The selective estrogen receptor modulators (SERMs) are another type of estrogen receptor ligands. The main difference between SERMs and xenoestrogens relies on the fact that SERMs present functional duality and are able to act both as agonists and antagonists of the estrogen receptors in different t
-
EPAC activation in VSMCs and ECs reverses several processes
2021-06-18

EPAC activation in VSMCs and ECs reverses several processes involved in the development of in-stent restenosis. Of particular relevance is the ability of EPAC1 to induce SOCS3 gene expression, as SOCS3 exerts multiple protective effects in both cell types, while immunohistochemical studies have show
-
In some cases more than one CYP enzyme may be
2021-06-18

In some cases, more than one CYP450 enzyme may be involved in the metabolism of a drug, and an Eadie–Hofstee plot is usually more reliable for assessing the involvement of multiple KC7F2 receptor (Bu, 2006). Therefore, we first plotted the Eadie–Hofstee curves and observed their shape to determine t
-
Introduction Activation of epidermal growth factor receptor
2021-06-18

Introduction Activation of epidermal growth factor receptor (EGFR)-receptor tyrosine kinases (RTKs) is a key factor in the progression of non-small cell lung cancer (NSCLC). EGFR-RTKs cause proliferation, invasion, metastasis, and angiogenesis, as well as suppress apoptosis, in lung adenocarcinoma
-
Regardless of its effect on EBV infection the
2021-06-18

Regardless of its effect on EBV infection, the chemokine system has been found to be regulated in both nasopharyngeal cancer and Hodgkin lymphoma. As such, Hodgkin and Reed–Sternberg (HRS) cells from Hodgkin lymphoma and nasopharyngeal carcinoma cells have been shown to express CXCL8 and CCL17. Furt
-
N acetylation by N acetyltransferase NAT is an
2021-06-18

N-acetylation by N-acetyltransferase (NAT) is an important metabolic pathway for some substances, and there are 2 functional NAT isoforms in humans—NAT1 and NAT2. Studies of etamicastat in healthy subjects showed an extensive N-acetylation of etamicastat to the inactive metabolite BIA 5-961, and a l
-
br Chagas disease Chagas disease an NTD caused by
2021-06-17

Chagas disease Chagas disease, an NTD caused by the protozoan Trypanosoma cruzi, affects 8–10 million people globally. More than 10,000 deaths are caused by the disease each year, and nearly 70 million people are susceptible to infection (Manne-Goehler, Umeh, Montgomery, & Wirtz, 2016). Chagas di
-
Hydrocortisone Functional studies suggested the presence of
2021-06-17

Functional studies suggested the presence of a cysLT1 receptor. We observed an LTD4-induced cytosolic calcium response, albeit one that was very weak by most standards. The magnitude of the average response was partially explained by the low percentage of Hydrocortisone showing a very transient res
-
Previously we had proposed three
2021-06-17

Previously we had proposed three possible models, with one being that hCrm1 fundamentally interacted more favorably or strongly with Rev-RRE complex, compared to mCrm1. We decided to test that model, which was the simplest and most straightforward, by both biochemical and genetic means. By using bac
-
Experiment B CP during fear acquisition normalizes fear pote
2021-06-17

Experiment 4B: CP154,526 during fear acquisition normalizes fear-potentiated startle and prevents exacerbation of contextual conditioned fear in SERT−/− rats. As genotypes differed markedly in basal fear acquisition, drug effects could differ strongly between genotypes. Therefore, all effects in th
-
Furthermore we explored the effect of PKC on SIRT
2021-06-17

Furthermore, we explored the effect of PKCζ on SIRT6 phosphorylation. Accumulating data showed that aPKC isoforms are involved in regulating lipid metabolism [41], [42], [43], [44], [45], [46], [47]. The aPKC activity was reported to play a dominant role in normal insulin signaling by activating PI3
-
br Diseases which have been treated with proteins
2021-06-17

Diseases which have been treated with proteins linked to HSA A number of therapeutic products conjugated to HSA have now been approved for clinical use (Table 2). For example, fatty YM201636 derivatives of human insulin bound to HSA have applications in the treatment of diabetes while paclitaxel
15903 records 643/1061 page Previous Next First page 上5页 641642643644645 下5页 Last page